NCT01770743View on ClinicalTrials.gov

A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

PHASE2CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2014

Conditions
Anthrax
Interventions
BIOLOGICAL

AV7909

Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant

BIOLOGICAL

BioThrax

Trial Locations (4)

29464

Costal Carolina Research, Mt. Pleasant

33143

Miami Research Associates, Miami

78130

Central Texas Allergy and Asthma, New Braunfels

84124

Jean Brown Research, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Emergent BioSolutions

INDUSTRY